BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:25 PM
 | 
Aug 20, 2007
 |  BC Extra  |  Clinical News

Liraglutide meets diabetes endpoints

Novo Nordisk (CSE:NVO; NVO) said liraglutide met the primary endpoint of improved glucose control in the double-blind, international Phase III LEAD-1 and LEAD-2...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >